260 related articles for article (PubMed ID: 31788896)
1. Engineered Nanoplatelets for Targeted Delivery of Plasminogen Activators to Reverse Thrombus in Multiple Mouse Thrombosis Models.
Xu J; Zhang Y; Xu J; Liu G; Di C; Zhao X; Li X; Li Y; Pang N; Yang C; Li Y; Li B; Lu Z; Wang M; Dai K; Yan R; Li S; Nie G
Adv Mater; 2020 Jan; 32(4):e1905145. PubMed ID: 31788896
[TBL] [Abstract][Full Text] [Related]
2. Preparation of Peptide and Recombinant Tissue Plasminogen Activator Conjugated Poly(Lactic-Co-Glycolic Acid) (PLGA) Magnetic Nanoparticles for Dual Targeted Thrombolytic Therapy.
Chen HA; Ma YH; Hsu TY; Chen JP
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32294917
[TBL] [Abstract][Full Text] [Related]
3. Novel and emerging therapies: thrombus-targeted fibrinolysis.
Lippi G; Mattiuzzi C; Favaloro EJ
Semin Thromb Hemost; 2013 Feb; 39(1):48-58. PubMed ID: 23034825
[TBL] [Abstract][Full Text] [Related]
4. Bioresponsive Polyphenol-Based Nanoparticles as Thrombolytic Drug Carriers.
Yu H; Palazzolo JS; Zhou J; Hu Y; Niego B; Pan S; Ju Y; Wang TY; Lin Z; Hagemeyer CE; Caruso F
ACS Appl Mater Interfaces; 2022 Jan; 14(3):3740-3751. PubMed ID: 35019268
[TBL] [Abstract][Full Text] [Related]
5. Comparative thrombolytic properties of tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (u-PA) and K1K2Pu (a t-PA/u-PA chimera) in a combined arterial and venous thrombosis model in the dog.
Lu HR; Wu Z; Pauwels P; Lijnen HR; Collen D
J Am Coll Cardiol; 1992 May; 19(6):1350-9. PubMed ID: 1342779
[TBL] [Abstract][Full Text] [Related]
6. Construction and evaluation of Fe₃O₄-based PLGA nanoparticles carrying rtPA used in the detection of thrombosis and in targeted thrombolysis.
Zhou J; Guo D; Zhang Y; Wu W; Ran H; Wang Z
ACS Appl Mater Interfaces; 2014 Apr; 6(8):5566-76. PubMed ID: 24693875
[TBL] [Abstract][Full Text] [Related]
7. Thrombolytic therapy based on fucoidan-functionalized polymer nanoparticles targeting P-selectin.
Juenet M; Aid-Launais R; Li B; Berger A; Aerts J; Ollivier V; Nicoletti A; Letourneur D; Chauvierre C
Biomaterials; 2018 Feb; 156():204-216. PubMed ID: 29216534
[TBL] [Abstract][Full Text] [Related]
8. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).
Agnelli G; Pascucci C; Nenci GG; Mele A; Bürgi R; Heim J
Thromb Haemost; 1993 Aug; 70(2):294-300. PubMed ID: 8236138
[TBL] [Abstract][Full Text] [Related]
9. Recombinant Plasminogen Activator Modified Nanoparticles for Targeting Thrombolysis in Branch Retinal Vein Occlusion.
Zhang H; Han S; Zhang L; Guo Y; Li Y
Cell Mol Biol (Noisy-le-grand); 2022 Mar; 68(3):201-212. PubMed ID: 35988180
[TBL] [Abstract][Full Text] [Related]
10. Multifunctional nanoagent for thrombus-targeted fibrinolytic therapy.
McCarthy JR; Sazonova IY; Erdem SS; Hara T; Thompson BD; Patel P; Botnaru I; Lin CP; Reed GL; Weissleder R; Jaffer FA
Nanomedicine (Lond); 2012 Jul; 7(7):1017-28. PubMed ID: 22348271
[TBL] [Abstract][Full Text] [Related]
11. Potent Thrombolytic Effect of
Martinez de Lizarrondo S; Gakuba C; Herbig BA; Repessé Y; Ali C; Denis CV; Lenting PJ; Touzé E; Diamond SL; Vivien D; Gauberti M
Circulation; 2017 Aug; 136(7):646-660. PubMed ID: 28487393
[TBL] [Abstract][Full Text] [Related]
12. Thrombolysis of canine femoral artery thrombus by a novel modified tissue-type plasminogen activator (E6010).
Suzuki N; Suzuki S; Nagaoka N; Mizuo H; Yuzuriha T; Yoshitake S; Kanmatuse K
Jpn J Pharmacol; 1994 Jul; 65(3):257-63. PubMed ID: 7799526
[TBL] [Abstract][Full Text] [Related]
13. New developments in thrombolytic therapy.
Collen D; Gold HK
Adv Exp Med Biol; 1990; 281():333-54. PubMed ID: 2129372
[TBL] [Abstract][Full Text] [Related]
14. Clinical experience with recombinant tissue plasminogen activator in the management of intracardiac and arterial thrombosis in children.
Olgun H; Buyukavci M; Ceviz N; Sahin IO; Yildirim ZK; Colak A; Tekgunduz KS; Caner I
Blood Coagul Fibrinolysis; 2014 Oct; 25(7):726-30. PubMed ID: 24806322
[TBL] [Abstract][Full Text] [Related]
15. A Fibrinogen-Mimicking, Activated-Platelet-Sensitive Nanocoacervate Enhances Thrombus Targeting and Penetration of Tissue Plasminogen Activator for Effective Thrombolytic Therapy.
Huang Y; Jiang J; Ren J; Guo Y; Zhao Q; Zhou J; Li Y; Chen R
Adv Healthc Mater; 2022 Oct; 11(19):e2201265. PubMed ID: 35864062
[TBL] [Abstract][Full Text] [Related]
16. Thrombolytic and pharmacokinetic properties of chimeric tissue-type and urokinase-type plasminogen activators.
Collen D; Lu HR; Lijnen HR; Nelles L; Stassen JM
Circulation; 1991 Sep; 84(3):1216-34. PubMed ID: 1909220
[TBL] [Abstract][Full Text] [Related]
17. Engineered Nanoplatelets for Enhanced Treatment of Multiple Myeloma and Thrombus.
Hu Q; Qian C; Sun W; Wang J; Chen Z; Bomba HN; Xin H; Shen Q; Gu Z
Adv Mater; 2016 Nov; 28(43):9573-9580. PubMed ID: 27626769
[TBL] [Abstract][Full Text] [Related]
18. An ultrasound-responsive nano delivery system of tissue-type plasminogen activator for thrombolytic therapy.
Uesugi Y; Kawata H; Jo J; Saito Y; Tabata Y
J Control Release; 2010 Oct; 147(2):269-77. PubMed ID: 20696194
[TBL] [Abstract][Full Text] [Related]
19. Recombinant Tissue Plasminogen Activator-conjugated Nanoparticles Effectively Targets Thrombolysis in a Rat Model of Middle Cerebral Artery Occlusion.
Deng J; Mei H; Shi W; Pang ZQ; Zhang B; Guo T; Wang HF; Jiang XG; Hu Y
Curr Med Sci; 2018 Jun; 38(3):427-435. PubMed ID: 30074208
[TBL] [Abstract][Full Text] [Related]
20. Elongated Plant Virus-Based Nanoparticles for Enhanced Delivery of Thrombolytic Therapies.
Pitek AS; Wang Y; Gulati S; Gao H; Stewart PL; Simon DI; Steinmetz NF
Mol Pharm; 2017 Nov; 14(11):3815-3823. PubMed ID: 28881141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
